Contributions
Abstract: PB2004
Type: Publication Only
Background
Hodgkin lymphoma (HL) is a most common malignancy affecting adolescents and young adults, but the standard treatment of adolescent patients is not well defined, particularly in the choice between pediatric and adult protocols.
Aims
To compare risk factors and therapeutic outcomes of adolescents and young adults with HL treated with ABVD.
Methods
98 patient patients treated in our department between 1994 and 2010 were analyzed: 33 adolescents between 15 and 21 years old, and 65 young adults between 22 and 39 years . All patients received as initial chemotherapy the ABVD protocol, followed in 65 (66.3%) by radiotherapy. We compared the patient characteristics of the two populations using Fisher's exact test. Survival was estimated using the Kaplan and Meier method, and compared by the log rank test. Cox proportional hazard regression was used to evaluate prognostic factors in adolescent patients.
Results
Histological type 2 and hypoalbuminemia were more frequent in adolescent patients (P = 0.05, P = 0.02 respectively). The incidence of other risk factors were without significant difference between the two populations. With a median follow-up of 67 months, overall survival (OS) and event-free survival (EFS) at 5 years were in the order of 79% and 72% for all patients. The overall rate of complete remission (CR) was 87.8% : 84.8% in adolescents and 89% in young adults (P = 0.53). The log rank test showed no significant difference between the two age groups, in terms of overall survival (P = 0.31) or EFS (P = 0.51). At 5 years, the estimate of OS and EFS are in the order of 77% and 74% for young adults, 73% and 68% for adolescents, respectively. After cox regression analysis, two factors were crucial for the survival of adolescent patients: the presence of bulky disease (P = 0.008) or an extranodal lymphoma involvement (P = 0.04).
Conclusion
The prognosis and risk factors of adolescent patients and young adults with HL treated with ABVD are similar. These data suggest that adult protocols can offer a safe and effective treatment option for adolescent patients.
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): Adolescents, chemotherapy, Hodgkin's Lymphoma, prognosis
Abstract: PB2004
Type: Publication Only
Background
Hodgkin lymphoma (HL) is a most common malignancy affecting adolescents and young adults, but the standard treatment of adolescent patients is not well defined, particularly in the choice between pediatric and adult protocols.
Aims
To compare risk factors and therapeutic outcomes of adolescents and young adults with HL treated with ABVD.
Methods
98 patient patients treated in our department between 1994 and 2010 were analyzed: 33 adolescents between 15 and 21 years old, and 65 young adults between 22 and 39 years . All patients received as initial chemotherapy the ABVD protocol, followed in 65 (66.3%) by radiotherapy. We compared the patient characteristics of the two populations using Fisher's exact test. Survival was estimated using the Kaplan and Meier method, and compared by the log rank test. Cox proportional hazard regression was used to evaluate prognostic factors in adolescent patients.
Results
Histological type 2 and hypoalbuminemia were more frequent in adolescent patients (P = 0.05, P = 0.02 respectively). The incidence of other risk factors were without significant difference between the two populations. With a median follow-up of 67 months, overall survival (OS) and event-free survival (EFS) at 5 years were in the order of 79% and 72% for all patients. The overall rate of complete remission (CR) was 87.8% : 84.8% in adolescents and 89% in young adults (P = 0.53). The log rank test showed no significant difference between the two age groups, in terms of overall survival (P = 0.31) or EFS (P = 0.51). At 5 years, the estimate of OS and EFS are in the order of 77% and 74% for young adults, 73% and 68% for adolescents, respectively. After cox regression analysis, two factors were crucial for the survival of adolescent patients: the presence of bulky disease (P = 0.008) or an extranodal lymphoma involvement (P = 0.04).
Conclusion
The prognosis and risk factors of adolescent patients and young adults with HL treated with ABVD are similar. These data suggest that adult protocols can offer a safe and effective treatment option for adolescent patients.
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): Adolescents, chemotherapy, Hodgkin's Lymphoma, prognosis